Christopher Dann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher Dann has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Dongbo Yang
University of Chicago, Chicago, IL
3 shared publications - Marsha Rich Rosner
Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA
3 shared publications Emily Shi
University of Chicago, Chicago, IL
2 shared publications- Galina Khramtsova
Department of Medicine, Center for Clinical Cancer Genetics and Global Health University of Chicago Chicago Illinois USA
2 shared publications - Kazuhiko Igarashi
Department of Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan; Center for Regulatory Epigenome and Diseases, Tohoku University Graduate School of Medicine, Sendai, Japan
2 shared publications - Letícia Stock
University of Chicago, Chicago, IL
2 shared publications
Latest Publications
- Open Access
PPARG governs adipogenic differentiation and cell state plasticity in well-differentiated and dedifferentiated liposarcoma
Well-differentiated and dedifferentiated liposarcoma (WD/DD LPS) represent a pathological continuum, often coexisting within the same tumor. While the dedifferentiated component is clinically aggressive, marked by rapid growth and metastatic potential, the evolutionary relationship between WD and DD LPS remains unknown. To investigate this, we performed single-nucleus RNA sequencing on matched WD and DD tumor regions. Both compartments shared a predominant population of undifferentiated mesenchymal cells, but only WD regions contained cells expressing adipocytic differentiation markers and PPARG target genes. Given the central role of PPARG in coordinating lipid metabolism and mitochondrial biogenesis during adipogenesis, these findings suggest that loss of this program may underlie the poorly differentiated, proliferative phenotype of DD LPS. Functional studies confirmed that PPARG activation in DD LPS cells induces lipid accumulation, reduces proliferation, and impairs tumor growth in vivo . These support a model in which impaired adipogenic differentiation underlies DD LPS pathology and identify PPARG as a potential therapeutic target to promote differentiation and suppress tumor progression. Teaser: PPARG reprograms DD liposarcoma toward adipogenesis, reducing proliferation and tumor growth
Open AccessPPARG governs adipogenic differentiation and cell state plasticity in well-differentiated and dedifferentiated liposarcoma
Well-differentiated and dedifferentiated liposarcoma (WD/DD LPS) represent a pathological continuum, often coexisting within the same tumor. While the dedifferentiated component is clinically aggressive, marked by rapid growth and metastatic potential, the evolutionary relationship between WD and DD LPS remains unknown. To investigate this, we performed single-nucleus RNA sequencing on matched WD and DD tumor regions. Both compartments shared a predominant population of undifferentiated mesenchymal cells, but only WD regions contained cells expressing adipocytic differentiation markers and PPARG target genes. Given the central role of PPARG in coordinating lipid metabolism and mitochondrial biogenesis during adipogenesis, these findings suggest that loss of this program may underlie the poorly differentiated, proliferative phenotype of DD LPS. Functional studies confirmed that PPARG activation in DD LPS cells induces lipid accumulation, reduces proliferation, and impairs tumor growth in vivo . These support a model in which impaired adipogenic differentiation underlies DD LPS pathology and identify PPARG as a potential therapeutic target to promote differentiation and suppress tumor progression. Teaser: PPARG reprograms DD liposarcoma toward adipogenesis, reducing proliferation and tumor growth
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (12_Supplem) , C070
Abstract C070: BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer
Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is more prevalent among African American and underserved female populations. Hypoxia has recently been identified as one of the main drivers of TNBC, particularly within the African American cohort. Therefore, it is important to identify and target key regulators of hypoxia. Here we show that the pro-metastatic transcription factor BACH1 is induced by hypoxia and regulates the hypoxia response in TNBC tumor cells. BACH1 protein is destabilized via an oxygen-dependent prolyl-hydroxylation pathway, akin to Hypoxia-inducible Factors (HIFs). BACH1 mutants (BACH1M) resistant to hydroxylation exhibit heightened transcriptional activity and metastatic potential both in vitro and in vivo. TGCA analysis reveals that TNBC exhibits elevated BACH1 mRNA and hypoxia signature, irrespective of racial ancestry. Nevertheless, racial disparities in BACH1 mRNA expression exist across all breast cancer subtypes (Basal, Her, LumA, LumB). Our findings suggest that BACH1 is an oxygen-sensitive mediator of hypoxia and a promising therapeutic target for mitigating hypoxia-induced pro-metastatic signaling and treatment resistance. These results also highlight the necessity of accounting for racial differences in BACH1 expression and function as a means of developing targeted therapy that takes into account racial disparities in TNBC. Citation Format: Long C. Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Leticia Stock, Madeline Henn, Galina Khramtsova, Wenchao Liu, Mitsuyo Matsumoto, Olufunmilayo Olopade, Kazuhiko Igarashi, Marsha Rosner. BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C070.
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (12_Supplem) , C070
Open AccessAbstract C070: BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer
Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is more prevalent among African American and underserved female populations. Hypoxia has recently been identified as one of the main drivers of TNBC, particularly within the African American cohort. Therefore, it is important to identify and target key regulators of hypoxia. Here we show that the pro-metastatic transcription factor BACH1 is induced by hypoxia and regulates the hypoxia response in TNBC tumor cells. BACH1 protein is destabilized via an oxygen-dependent prolyl-hydroxylation pathway, akin to Hypoxia-inducible Factors (HIFs). BACH1 mutants (BACH1M) resistant to hydroxylation exhibit heightened transcriptional activity and metastatic potential both in vitro and in vivo. TGCA analysis reveals that TNBC exhibits elevated BACH1 mRNA and hypoxia signature, irrespective of racial ancestry. Nevertheless, racial disparities in BACH1 mRNA expression exist across all breast cancer subtypes (Basal, Her, LumA, LumB). Our findings suggest that BACH1 is an oxygen-sensitive mediator of hypoxia and a promising therapeutic target for mitigating hypoxia-induced pro-metastatic signaling and treatment resistance. These results also highlight the necessity of accounting for racial differences in BACH1 expression and function as a means of developing targeted therapy that takes into account racial disparities in TNBC. Citation Format: Long C. Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Leticia Stock, Madeline Henn, Galina Khramtsova, Wenchao Liu, Mitsuyo Matsumoto, Olufunmilayo Olopade, Kazuhiko Igarashi, Marsha Rosner. BACH1 regulates the hypoxia response and metastasis in triple negative breast cancer [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C070.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4807
Abstract 4807: BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer
Hypoxia is an important hallmark of aggressive solid tumors. Here we show that the pro-metastatic BTB and CNC homology 1 (BACH1) transcription factor is prolyl-hydroxylated by the HIF Prolyl Hydroxylase 1 (PHD1) in an oxygen-dependent manner. Using mass spectrometry, we identified two major prolyl hydroxylation sites in BACH1 and demonstrate that prolyl hydroxylation increased protein turnover in normoxia. Notably, a clinically relevant BACH1 mutant (BACH1M) resistant to hydroxylation displays enhanced BACH1 DNA binding capacity. Triple-negative breast cancer (TNBC) cells expressing BACH1M showed higher invasion in vitro and increased metastasis in vivo. Loss of BACH1 reduced the cellular transcriptional hypoxic response. Under hypoxia, BACH1 increases chromatin accessibility and gene expression through chromatin remodeling involving direct BACH1 binding and indirect epigenetic regulation. These results indicate that hypoxia stabilizes and enhances the pro-metastatic transcriptional activity of BACH1 through loss of prolyl hydoxylation in TNBC. Our findings identify BACH1 as an oxygen sensitive effector of the hypoxia response and a clinically relevant target for attenuating hypoxia induced, pro-metastatic signaling and therapeutic resistance in cancers. Citation Format: Long Chi Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Joseph Wynne, Letícia Stock, Madeline Henn, Zeyu Qiao, Andrea Valdespino, Raven Watson, Wenchao Liu, Lydia Robinson-Mailman, Galina Khramtsova, Mitsuyo Matsumoto, Raymond Moellering, Olufunmilayo I. Olopade, Kazuhiko Igarashi, Marsha R. Rosner. BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4807.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4807
Abstract 4807: BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer
Hypoxia is an important hallmark of aggressive solid tumors. Here we show that the pro-metastatic BTB and CNC homology 1 (BACH1) transcription factor is prolyl-hydroxylated by the HIF Prolyl Hydroxylase 1 (PHD1) in an oxygen-dependent manner. Using mass spectrometry, we identified two major prolyl hydroxylation sites in BACH1 and demonstrate that prolyl hydroxylation increased protein turnover in normoxia. Notably, a clinically relevant BACH1 mutant (BACH1M) resistant to hydroxylation displays enhanced BACH1 DNA binding capacity. Triple-negative breast cancer (TNBC) cells expressing BACH1M showed higher invasion in vitro and increased metastasis in vivo. Loss of BACH1 reduced the cellular transcriptional hypoxic response. Under hypoxia, BACH1 increases chromatin accessibility and gene expression through chromatin remodeling involving direct BACH1 binding and indirect epigenetic regulation. These results indicate that hypoxia stabilizes and enhances the pro-metastatic transcriptional activity of BACH1 through loss of prolyl hydoxylation in TNBC. Our findings identify BACH1 as an oxygen sensitive effector of the hypoxia response and a clinically relevant target for attenuating hypoxia induced, pro-metastatic signaling and therapeutic resistance in cancers. Citation Format: Long Chi Nguyen, Christopher Dann, Dongbo Yang, Emily Shi, Thomas Li, Joseph Wynne, Letícia Stock, Madeline Henn, Zeyu Qiao, Andrea Valdespino, Raven Watson, Wenchao Liu, Lydia Robinson-Mailman, Galina Khramtsova, Mitsuyo Matsumoto, Raymond Moellering, Olufunmilayo I. Olopade, Kazuhiko Igarashi, Marsha R. Rosner. BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4807.
- Open Access
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Open AccessCannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.